Cancer Immunology, Immunotherapy

, Volume 32, Issue 6, pp 335–341 | Cite as

In vitro immunomodulating effect of protein-bound polysaccharide, PSK on peripheral blood, regional nodes, and spleen lymphocytes in patients with gastric cancer

  • Yoshinori Nio
  • Takahiro Shiraishi
  • Michihiko Tsubono
  • Hideki Morimoto
  • Chen-Chiu Tseng
  • Shiro Imai
  • Takayoshi Tobe
Original articles


PSK, a protein-bound polysaccharide, has been widely used for cancer immunotherapy in Japan. However, the mechanism of its immunomodulatory effect has not been fully clarified. In the present study the in vitro effect of PSK on the lymphocytes of patients with gastric cancer was studied. Culturing lymphocytes with PSK at 5–100 µg/ml increased the level of DNA synthesis, and augmented the cytotoxicities against K562 and KATO-3. Flow-cytometric analysis also showed an increase in the proportion of interleukin-2 (IL-2)-receptor-positive cells after the lymphocytes were cultured with PSK. However the cytotoxicity of cells cultured with PSK was not augmented by the addition of recombinant interferon γ (rIFNγ) and rIL-2. Further experiments using fractionated PSK showed that its biological action is present mainly in fractions having molecular masses >105Da. However, these immunomodulations were not seen in all patients. These results suggest that the susceptibility of lymphocytes to PSK may be different in each patients, and that the immunomodulation by PSK may be mediated by mechanisms independent of IFN and IL-2.

Key words

PSK NK cells Immunotherapy Gastric cancer 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Akiyama J, Kawamura T, Gotohda E, Yamada Y, Hosokawa M, Kodama T, Kobayashi H (1077) Immunochemotherapy of transplanted KMT-17 tumor WKA rated by combination of cyclophosphamide and immunostimulatory protein-bound polysaccharide isolated from basidiomycetes. Cancer Res 37: 3042–3045Google Scholar
  2. 2.
    Ebihara K, Minamishima Y (1984) Protective effect of biological response modifiers on murine cytomegalovirus infection. J Virol 51: 117–122Google Scholar
  3. 3.
    Ebina T, Kohya H (1988) Antitumor effector mechanism at a distant site in the double grafted tumor system of PSK, a protein-bound polysaccharide preparation. Jpn J Cancer Res (Gann) 79: 957–964Google Scholar
  4. 4.
    Ebina T, Kohya H, Yamaguchi T, Ishida N (1986) Antimetastatic effect of biological response modifiers in the “double grafted tumor system”. Jpn J Cancer Res (Gann) 77: 1034–1042Google Scholar
  5. 5.
    Ehrke MJ, Reino JM, Eppolito C, Mihich E (1983) The effect of PS-K, a protein bound polysaccharide, on immune responses against allogeneic antigens. Int J Immunopharmacol 5: 35–42Google Scholar
  6. 6.
    Hosokawa M, Mizukoshi T, Morikawa K, Xu Z, Kobayashi H (1986) The therapeutic effects of an immunopotentiator, PS-K, on 3-methylcholanthrene-induced autochthonous tumors in C57BL/6 mice in combination with the surgical removal of primary sites. Cancer Immunol Immunother 22: 181–185Google Scholar
  7. 7.
    Kano T, Kumashiro R, Tamada R, Kodama Y, Inokuchi K (1981) Late results of postoperative long term cancer chemotherapy for advanced carcinoma of the stomach. Jpn J Surg 11: 291–296Google Scholar
  8. 8.
    Kato H, Kin R, Yamamura Y, Tanigawa M, Sano H, Sugino S, Kondo M (1987) Tumor inhibitory effect of polymorphonuclear leukocytes (PMN) induced by PSK in the peritoneal cavity of tumorbearing mice. J Kyoto Prefect Univ Med 96: 927–938Google Scholar
  9. 9.
    Kikuchi Y, Kizawa I, Oomori K, Iwano I, Kita T, Kato K (1988) Effects of PSK on interleukin-2 production by peritoneal lymphocytes of patients with advanced ovarian carcinoma during chemotherapy. Jpn J Cancer Res (Gann) 79: 125–130Google Scholar
  10. 10.
    Kitani H, Tsuru S, Oguchi M, Watanabe M, Zinnaka Y (1984) Effect of PSK in interferon production in tumor-bearing mice. J Clin Lab Immunol 15: 211–214Google Scholar
  11. 11.
    Kondo T, Sakamoto J, Ichihashi H, Kamei H (1981) Effect of alternating administration of PS-K and carbazilquinone in tumor-bearing mice. Jpn J Cancer Res (Gann) 72: 293–299Google Scholar
  12. 12.
    Mickey DD (1985) Combined therapeutic effects on an immunomodulator, PSK, and chemotherapy with carboquone on rat bladder carcinoma. Cancer Chemother Pharmacol 15: 54–58Google Scholar
  13. 13.
    Mitomi T, Tsuchiya S, Iijima N, Aso K, Suzuki K, Nishiyama K, Amano T, Takahashi T, Murayama N, Oka H, Ooya K, Noto T, Ogawa N (1989) Randomized controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. Jpn J Cancer Chemother 16: 2241–2249Google Scholar
  14. 14.
    Mizushima Y, Yuhki N, Hosokawa M, Kobayashi H (1982) Diminution of cyclophosphamide-induced suppression of antitumor immunity by an immunomodulator PS-K and combined therapeutic effects of PS-K and cyclophosphamide on transplanted tumor in rats. Cancer Res 42: 5176–5180Google Scholar
  15. 15.
    Nakazato H, Koike A, Ichihara H, Saji S, Danno M, Ogawa N (1989) An effect of adjuvant immunochemotherapy using krestin and 5-FU on gastric cancer patients with radical surgery (first report) — a randomized controlled trial by the cooperative study group. Jpn J Cancer Chemother 16: 2563–2576Google Scholar
  16. 16.
    Nio Y, Tsuchitani T, Imai S, Shiraishi T, Kan N, Ohgaki K, Tobe T (1988) Immunomodulating effects of oral administration of PSK: II. Its effects on mice with cecal tumors. J Jpn Soc Cancer Ther 23: 1068–1076Google Scholar
  17. 17.
    Ogoshi K, Mitomi T (1989) Clinical effects of PSK on esophageal and gastric cancer patients and usefulness of serum level of glycoproteins and HLA antigens as prognostic indicators. J Jpn Surg Soc 90: 1443–1446Google Scholar
  18. 18.
    Ohno R, Yamada K, Masaoka T, Ohshima T, Amaki I, Hirota Y, Horikoshi N, Horiuchi A, Imai K, Kimura I, Kitajima K, Nakamura H, Nakamura T, Ohta Y, Sakai Y, Tanaka M, Tsubaki K, Uchino H, Ogawa N, Kimura K (1984) A randomized trial of chemoimmunotherapy of acute nonlymphocytic leukemia in adults using a protein-bound polysaccharide preparation. Cancer Immunol Immunother 18: 149–154Google Scholar
  19. 19.
    Toge T, Yamaguchi Y, Kegoya Y, Baba N, Yanagawa E, Hattori T (1989) Blocking of lymphocyte surface binding sites for the soluble suppressor factor by protein-bound polysaccharide, PSK. Int J Immunopharmacol 11: 9–12Google Scholar
  20. 20.
    The General Rule for Gastric Cancer Study (1985) 11th edn, Japanese research Society, Kanehara SyuppanGoogle Scholar
  21. 21.
    Tsuchiotani T, Nio Y, Imai S, Shiraishi T, Kan N, Ohgaki K, Tobe T (1987) Effects of oral administration of PSK on immune responses. I. Correlation ofin vivo effects within vitro biological activity. J Jpn Soc Cancer Ther 22: 1195–1202Google Scholar
  22. 22.
    Tsukagoshi S (1975) Fundamental approaches to cancer immunotherapy using a protein-bound polysaccaride, PSK, with special reference to its clinical application. In: Host Defense against Cancer and its Potentiation, ed., D. Mizuno et al. Univ. of Tokyo Press, Tokyo/Univ. Park Press, Baltimore, pp 365–377Google Scholar
  23. 23.
    Tsuru S, Nomoto K (1983) Effects of PSK on specific tumor immunity to syngeneic tumor cells. J Clin Lab Immunol 14: 215–219Google Scholar
  24. 24.
    Usui S, Urano M, Koike S, Kobayashi Y (1976) Brief communication: Effect of PSK, a protein polysaccharide, on pulmonary metastases of a C3H mouse squamous cell carcinoma. J Natl Cancer Inst 56: 185–187Google Scholar

Copyright information

© Springer-Verlag 1991

Authors and Affiliations

  • Yoshinori Nio
    • 1
  • Takahiro Shiraishi
    • 1
  • Michihiko Tsubono
    • 1
  • Hideki Morimoto
    • 1
  • Chen-Chiu Tseng
    • 1
  • Shiro Imai
    • 1
  • Takayoshi Tobe
    • 1
  1. 1.First Department of Surgery, Faculty of MedicineKyoto UniversityKyotoJapan

Personalised recommendations